WHO Reviews Wolbachia Strategy for Mosquito-Borne Diseases

WHO said the work reflects increasing global interest in the intervention, with a growing number of countries already testing or using Wolbachia programmes to help reduce disease transmission.

The World Health Organization (WHO) has launched an updated review of Wolbachia-based mosquito control strategies as interest continues to grow in the approach as a tool for reducing the spread of dengue and other mosquito-borne diseases.

The review will examine the full body of available evidence on Wolbachia population replacement, including research published since WHO's original assessment. The organization will also evaluate population suppression methods that use Wolbachia and assess factors that could influence how countries adopt and implement the technology.

WHO said the work reflects increasing global interest in the intervention, with a growing number of countries already testing or using Wolbachia programmes to help reduce disease transmission.

How Wolbachia Helps Fight Disease

Wolbachia is a naturally occurring bacterium that can be introduced into Aedes mosquito populations. Once established, it reduces the mosquitoes' ability to transmit viruses such as dengue, which continues to pose a major public health threat in many tropical and subtropical regions.

In 2020, WHO's Vector Control Advisory Group reviewed evidence from multiple field trials and concluded that the population replacement approach had demonstrated measurable public health benefits. That finding led to the recommendation that WHO begin developing formal guidance for countries considering the intervention. Since then, new studies from a wider range of locations and operating environments have added to the evidence base, prompting the need for a comprehensive reassessment.

Guidance Expected After Expert Review

As part of the process, WHO is also preparing an operational manual designed to help countries plan and implement Wolbachia population replacement programmes where appropriate. The updated evidence will be reviewed by WHO's newly established Integrated Vector Control Guideline Development Group, which is expected to meet during the first quarter of 2027. The group will assess the available research, evaluate benefits and risks, and consider practical implementation issues before developing recommendations.

Following WHO's formal review and approval procedures, recommendations could be published in late 2027. The operational manual is expected to be finalized afterward, depending on the outcome of the guideline development process. WHO said the aim is to provide countries with clear, evidence-based guidance that supports informed decision-making while ensuring that mosquito control programmes remain safe, effective and suited to local public health needs.

The organization noted that growing interest from governments and health partners highlights the importance of developing internationally recognized recommendations as countries continue searching for innovative ways to combat mosquito-borne diseases.